HPH-15, a compound developed by Kumamoto University, reduces blood glucose and fat accumulation more effectively than metformin, with added benefits like antifibrotic properties and a safer profile. This innovation may revolutionize diabetes treatment.
Scientists at Kumamoto University have unveiled a novel compound, HPH-15, which has dual effects: reducing blood glucose levels and combating fat accumulation. This breakthrough represents a significant advancement in diabetes treatment innovation.
Key findings include:
- Enhanced Efficacy: HPH-15 activated AMPK and promoted glucose uptake at concentrations 200 times lower than metformin.
- Fat Reduction: The compound decreased subcutaneous fat by 44% and mitigated fatty liver more effectively than metformin in preclinical trials.
- Safety Profile: Lactic acid production, a concern with metformin, was either comparable or lower with HPH-15, suggesting reduced risks of lactic acidosis.
https://scitechdaily.com/better-than-metformin-new-diabetes-wonder-drug-slashes-fat-and-blood-sugar/
Reference: “An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models” by Tsugumasa Toma, et al., 9 September 2024, Diabetologia .
DOI: 10.1007/s00125-024-06260-y
